Estimation of Public Health Impact with Use of Nirsevimab During the 2024–2025 RSV Season in the USA: a Modeling Study
Abstract Introduction Respiratory syncytial virus (RSV) is a leading cause of medically attended lower respiratory tract disease (MA-LRTD) and hospitalization among infants in the USA. With the introduction in 2023 of nirsevimab, a long-acting monoclonal antibody for infant RSV prevention, early dat...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , , , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Adis, Springer Healthcare
2026-02-01
|
| Σειρά: | Pulmonary Therapy |
| Θέματα: | |
| Διαθέσιμο Online: | https://doi.org/10.1007/s41030-026-00348-z |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|